Regeneron Pharmaceuticals (REGN) Convertible Debt (2011 - 2015)

Regeneron Pharmaceuticals' Convertible Debt history runs 5 years deep, the most recent figure standing at $30.7 million for Q3 2015.

• In Q3 2015, Convertible Debt fell 89.33% year-over-year to $30.7 million; the TTM figure through Sep 2015 stood at $30.7 million (down 89.33% YoY), while the FY2014 annual figure was $146.8 million, down 54.18% from the prior year.
• Convertible Debt was $30.7 million for Q3 2015 at Regeneron Pharmaceuticals, up from $30.4 million in the prior quarter.
• In the past five years, Convertible Debt ranged from a high of $326.7 million in Q1 2014 to a low of $30.4 million in Q2 2015.
• Historically, Convertible Debt has averaged $245.1 million across 5 years, with a median of $286.7 million in 2012.
• The sharpest annual moves came in 2014 and 2015: Convertible Debt gained 8.07% in 2014, then sank 89.33% in 2015.
• A 5-year view of Convertible Debt shows it stood at $275.0 million in 2011, then advanced by 7.82% to $296.5 million in 2012, then rose by 8.03% to $320.3 million in 2013, then plunged by 54.18% to $146.8 million in 2014, then slumped by 79.07% to $30.7 million in 2015.
• The last three Convertible Debt figures came in at $30.7 million (Q3 2015), $30.4 million (Q2 2015), and $144.1 million (Q1 2015), per Business Quant data.